PARP1 and ovarian cancer: ABT-263 disrupts the interaction of BCL-2/BC-XL with pro-death proteins and induces BAX translocation, cytochrome c release, and ultimately apoptosis.463,1164 Navitoclax inhibits growth in multiple preclinical tumor models1165 and is currently being evaluated in combination with the PARP inhibitor olaparib for the treatment of TNBC and ovarian cancer in a phase I clinical trial (NCT05358639).